Selecta Biosciences to Host Conference Call and Webcast to Discuss Second Quarter 2021 Financial Results and Provide Business Update

Rhea-AI Summary

On August 5, 2021, Selecta Biosciences, Inc. (NASDAQ: SELB) announced a conference call scheduled for August 12, 2021, at 8:30 a.m. ET. The call will discuss financial results for Q2 2021, which ended on June 30, 2021, along with a business update. Selecta utilizes its ImmTOR™ platform to develop immunology therapies aimed at mitigating unwanted immune responses. The company has several proprietary and partnered programs focused on various therapies, including gene and enzyme therapies, indicating diverse growth avenues.

Positive

• Plans to discuss Q2 2021 financial results and business updates, indicating transparency and investor engagement.
• ImmTOR™ platform shows potential for amplifying the efficacy of biologic therapies.

Negative

• None.

WATERTOWN, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that it plans to host a conference call on Thursday, August 12, 2021, at 8:30 a.m. ET to discuss its financial results for the quarter ended June 30, 2021 and provide a business update.

Individuals may participate in the live call via telephone by dialing (844) 845-4170 (domestic) or (412) 717-9621 (international) and may access a teleconference replay for one week by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and using confirmation code 10147802. Investors and the public can access the live and archived webcast of this call and a copy of the presentation via the Investors & Media section of the company’s website, www.selectabio.com.

About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit www.selectabio.com.

For Investors:
Bruce Mackle
LifeSci Advisors, LLC
+1-929-469-3859
bmackle@lifesciadvisors.com

For Media:
Brittany Leigh, Ph.D.
LifeSci Communications, LLC
+1-646-751-4366
bleigh@lifescicomms.com

Source: Selecta Biosciences, Inc.

FAQ

What are the financial results for SELB for Q2 2021?

Selecta Biosciences will disclose its Q2 2021 financial results during the conference call on August 12, 2021.

When is Selecta Biosciences' conference call?

The conference call is scheduled for August 12, 2021, at 8:30 a.m. ET.

What is the ImmTOR™ platform of Selecta Biosciences?

The ImmTOR™ platform develops tolerogenic therapies to mitigate unwanted immune responses, with potential applications in enhancing biologic therapies.

How can I participate in the SELB conference call?

You can join the call by dialing (844) 845-4170 for domestic or (412) 717-9621 for international participants.